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Introduction. The aim of our study was to analyze the number and structure of patients diagnosed and treated due to 
cancers of lips, mouth and throat in Poland between 2008 and 2015.
Material and methods. Secondary statistical analysis of data obtained from the Polish National Cancer Registry (KRN) 
and Polish National Health Fund (NFZ), concerning patients diagnosed for the first time between 2008 and 2015.
Results. Based on the available data, in total there were 30 800 new cases of cancers in population of Poland, and 29 800 
people starting their treatment financed from the National Health Fund.
Discussion. Cancers of the discussed locations, considered individually, are often rare diseases, with the incidence counted 
in hundreds of people per year in the entire Polish population. Due to the etiology and course, however, they should be 
analyzed together, which means that they become a significant group. 
Conclusions. In recent years, the annual incidence of these tumours was about 4000 cases, 70% of them were men. There 
is an approximately 10% difference in the number of registered cases of these cancers in NFZ databases. The creation of a 
medical register, including administrative, epidemiological and clinical data, would significantly improve the observation 
of the population of patients with these tumours.
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Introduction
Neoplasms of the head and neck (H&N) are classified together, 
due to their similar aetiology, anatomical pathology and clinical 
course. It is estimated that they form around 6% of all cases 
of cancer and are the reason of 5% of deaths. Approximately 
600 000 of new diagnoses of cancer from this group are made 
worldwide [1–3]. The Cancer Incidence in Five Continents 
(CI5) studies demonstrate a worrying increase of incidence in 
Central Europe [4]. According to the National Cancer Registry 
(KRN) in Poland, 4389 persons were diagnosed in 2015: 3140 
men and 1249 women. The peak incidence is observed at 
the seventh decade of life, in women it remains at a constant 
level, starting in the seventh decade of life. According to KRN, 
the incidence in Poland is higher than average for the other 
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European Union countries, approximately 1.4 times higher 
for men and 1.2 times higher for women. Another source of 
incidence data for Poland is the National Health Fund (NFZ). 
This institution is responsible for financing practically all the 
oncology treatments in Poland. Moreover, it is notified about all 
the services used by patients both in outpatient and hospital 
treatment. The goal of the conducted analysis was to compare 
the incidence and prevalence of head and neck cancers in 
Poland with health care services utilisation, based on NFZ data 
from the years 2008–2017.
Materials and methods
The method used is the secondary statistical analysis of data 
reported to the national payer – the National Health Fund (NFZ) 
by medical institutions with an indicated diagnosis of lip, oral 
cavity and pharyngeal cancer in the years 2008–2017 based on 
ICD-10 classification of diseases. This method has been already 
used for similar analyses [5–8]. The analysis included all the 
reported information on interventions in patients undergoing 
therapy after a diagnosis of lip, oral cavity and pharyngeal 
cancer (according to ICD-10 = C00.X – C14.X [9, 10] as the 
main reason for the intervention; the NFZ databases record all 
patients whose therapy was financed from the public funds). 
In order to observe the rules for processing sensitive data, such 
as personal ID (in Poland PESEL – Universal Electronic System 
for Registration of the Population), the data were anonymised 
during the analysis, obtaining the results by processing data 
sets without sensitive personal data (according to the General 
Data Protection Regulation) [11]. Indicators of incidence and 
annual and long-term prevalence were calculated (in the years 
2008–2017 – 10-year prevalence and indicator of 10-year pre-
valence per 100 000 inhabitants; in this case the average num-
ber of inhabitants of Poland in the years 2008–2017 was used 
as the denominator). Demographical data (as of 31 December 
of the given year) used in order to standardise the incidence 
and prevalence indicators was downloaded from the Central 
Statistical Office (GUS) website, separately for each year [12]. 
Additionally, the obtained results were compared to the 
data established by the National Cancer Registry (KRN – last 
available KRN report on cancers refers to the year 2015), con-
firming the treatment of cancer using verification algorithms 
operating in the NFZ’s internal tool – the Disease Treatment 
Registry (RLC). The principles on which the verification algo-
rithms operate are presented in table I. This has established 
the level of overdiagnosis of lip, oral cavity and pharyngeal 
cancer in Poland, this method was already used in analyses 
[13]. SQL (structured query language) tools were used to 
extract the data, using a filter in accordance with the ICD-10 
diagnoses specified in the assumptions. 
Results
Based on the data for the population of Poland in the years 
2008–2017, a total of 120 752 diagnoses of lip, oral cavity and 
pharyngeal cancer were established in men and women. Men 
constituted a significantly higher percentage of this group – 
64%. A total of 46 038 patients underwent hospital treatment, 
of which approx. 72% were men. The number of patients 
Table I. Principles of verification algorithms used in the Disease Treatment 
Registry (RLC) for oncology 
Data on patients diagnosed with a malignant neoplasm by the 
RLC system are analysed for:
1. Repeatability of the given diagnosis = in order to consider 
a diagnosis established it has to dominate with a given patient and 
be indicated at least 3 times
2. Indicated diagnostic/therapeutic activities which confirm a cancer 
is a situation where a patient with a diagnosed cancer underwent
3. Surgery:
Radiotherapy
Chemotherapy
Figure 1. Number of patients registered in KRN and commencing treatment according to RLC
2008 2009 2010 2011 2012 2013 2014 2015
NFZ 3613 3601 3514 3618 3716 3827 3951 3954
KRN 3445 3527 3669 3632 3824 3975 4297 4389
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Table II. Number of patients reported in individual years with a diagnosis of a malignant neoplasm, taking into account their sex and selected type of health 
care services
  2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Number of patients in all types of services
10-year; men 78 048
10-year; women 42 704
men 14 413 15 347 15 218 15 147 15 378 15 609 15 942 15 702 15 978 15 928
women 7519 8288 7847 7910 7976 8008 8279 8236 8206 8412
Number of patients in hospital treatment 
10-year; men 33 094
10-year; women 12 944
men 4357 4141 4094 3801 3706 3772 3861 4627 4897 4833
women 1698 1655 1554 1425 1478 1565 1506 1774 1874 2004
Number of patients in specialist outpatient care
10-year; men 52 546
10-year; women 25 859
men 10 604 10 706 10 817 11 109 11 440 11 763 12 227 12 107 12 501 12 616
women 5309 5358 5353 5644 5738 6002 6317 6182 6326 6568
Table III. Comparison of KRN and NFZ data for individual types of services
2008 2009 2010 2011 2012 2013 2014 2015
KRN 3445 3527 3669 3632 3824 3975 4297 4389
ALL 21 932 23 635 23 065 23 057 23 354 23 617 24 221 23 938
AOS 15 913 16 064 16 170 16 753 17 178 17 765 18 544 18 289
SZP 6055 5796 5648 5226 5184 5337 5367 6401
KRN – National Cancer Registry, ALL – the number of patients diagnosed with head and neck cancer (ICD10) in all types of services, AOS – number of pa tients  in specialist 
outpatient care, SZP – number of pa tients in hospital treatment
Table IV. Percentage of patients undergoing causal treatment compared to the number of patients reported by medical institutions to the NFZ
2008 2009 2010 2011 2012 2013 2014 2015
ALL 15.7% 14.9% 15.9% 15.8% 16.4% 16.8% 17.7% 18.3%
AOS 21.6% 22.0% 22.7% 21.7% 22.3% 22.4% 23.2% 24.0%
SZP 56.9% 60.9% 65.0% 69.5% 73.8% 74.5% 80.1% 68.6%
ALL – the number of patients diagnosed with head and neck cancer (ICD10) in all types of services, AOS – number of pa tients  in specialist outpatient care, SZP – number of pa-
tients in hospital treatment
indicated in hospital treatment forms 27–28% of the general 
number of patients declared by medical institutions, whereas 
specialist outpatient treatment has registered 78 405 patients 
of patients, including approx. 67% men. The number of pa-
tients indicated in specialist outpatient treatment amounted 
to approx. 74% of all indicated patients (Tab. II).
Assuming that the patient’s path starts with a suspicion of 
cancer leading to specialist diagnostics, and then enhanced 
diagnostics and therapy in hospital treatment, from all pa-
tients diagnosed with ICD-10 diagnosis of lip, oral cavity and 
pharyngeal cancer approx. 74% end in specialised outpatient 
care (specialised diagnostics), and approx. 27–28% end up in 
hospital treatment (enhanced diagnostics and therapy). Over 
10 years the analysed data on the number of patients are highly 
stable, and the 10-years dynamics is positive and amounts to 
approx. 1–2%. A comparison of the number of patients indica-
ted for all types of services, in specialist outpatient care (AOS) 
and in hospital treatment (SZP) to the number of confirmed 
cases (KRN) is presented in table III. 
The reference source of incidence data in Poland is the 
KRN, figures of which were compared with the number of 
new patients treated due to H&N cancers (Fig. 1). In order to 
establish the category of  “new treated patients” and to enable 
comparison of the NFZ data with the KRN ones, verification 
algorithms has been prepared (Tab. I).
Comparison of KRN data and the number of confirmed 
tumours according to NFZ demonstrates that the data sets are 
highly conforming. The highest conformity (practically 100%) 
occurred in 2011. The data difference between the sets in 
2015 amounts to approx. 10%. Verification algorithms created 
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in order to confirm the electronic databases data enable the 
estimation of the number of patients treated for H&N cancer 
with a confirmed diagnosis. By comparing the KRN data and 
the data reported by medical entities, we can assess the per-
centage of patients reported to NFZ for whom the occurrence 
of cancer was confirmed and causal treatment (therapy) was 
commenced (Tab. IV). 
The percentage of patients with a confirmed malignant 
neoplasm compared to all the patients reported by medical 
institutions with a H&N neoplasm demonstrates a growth 
tendency. This trend is observed both as a total for all types of 
services, in specialist outpatient care and in hospital treatment. 
In hospital treatment the highest percentage of patients have a 
confirmed diagnosis of a malignant neoplasm or commenced 
therapy (in 2014 this was over 80% of the patients). Due to 
the highest compatibility of data between the data reported 
for hospital treatment and KRN, the standardised indicators 
and further analyses were calculated based on this type of 
services (Tab. III). Proportions of 10-year prevalence indicators 
by gender indicate increased prevalence among 2.73 (men): 
1 (women) (Tab. V).
Annual prevalence indicators demonstrate high stability, 
average per year over the examined period for hospital treat-
ment amount to 23/100 000 M (men); 8/100 000 W (women). 
Prevalence divided into individual groups of diagnoses under 
hospital treatment is presented in table VI. 
Dynamics of the number of reported patients in all types 
of cancer under analysis since 2012 demonstrates a decreasing 
tendency. Over the analysed period, the highest number 
of patients were diagnosed with a malignant neoplasm of 
other and unspecified parts of the tongue (C02.X = 791.3). 
At the second place in the analysed group there is a mali-
gnant neoplasm of the floor of the mouth (C04.X = 740.8), in 
case of this tumour the dynamics is upwards over the entire 
analysed period. The third most frequent tumour is the mali-
gnant neoplasm of tonsil (C09.X = 724.9). The least frequently 
diagnosed was the malignant neoplasm of gum (C03.X = 
173.9) and a malignant neoplasm with other and unspecified 
large glands (C08.X = 175.9). Standardisation of data based 
on the population enables the assessment of the frequency 
of occurrence of a given neoplasm within the area of Poland 
and the comparison of the frequency of occurrence of H&N 
neoplasms (Tab. VII). Standardised prevalence indicators for 
the tumours: C00.X from 1.73 (2008) to 1.42 (2017); C11.X from 
1.01 (2008) to 0.93 (2017); C14.X from 1.04 (2008) to 0.55 (2017) 
have a decreasing tendency. Other neoplasms with a high 
Table V. The annual and periodical (10-year) prevalence indicator for patients reported in individual years with the diagnosis of lip, oral cavity and pharyngeal 
cancer taking into account sex, undergoing hospital treatment per 100 000 province inhabitants
  2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
10-year; men 463
10-year; women 236
men 24 22 22 20 20 20 21 25 26 26
women 9 8 8 7 7 8 8 9 9 10
Table VI. Number of patients in individual years taking into account the ICD-10 group as a part of hospital treatment 
  2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Average
C00 659 582 564 545 496 481 474 520 544 544 540.9
C01 445 419 406 388 325 325 337 394 422 420 388.1
C02 744 771 749 653 675 745 738 884 960 994 791.3
C03 183 147 134 156 159 168 169 222 195 206 173.9
C04 687 732 726 679 637 602 683 871 876 915 740.8
C05 283 283 285 235 209 234 223 286 291 284 261.3
C06 361 354 353 349 389 387 369 429 507 526 402.4
C07 418 371 367 317 350 363 342 406 437 417 378.8
C08 194 198 188 120 152 158 153 202 180 214 175.9
C09 755 657 595 563 588 637 645 893 979 937 724.9
C10 621 574 586 511 458 476 447 579 589 568 540.9
C11 385 449 375 337 319 326 305 301 390 359 354.6
C12 158 155 189 192 148 163 181 222 249 272 192.9
C13 741 629 628 609 602 634 614 724 761 743 668.5
C14 396 316 317 260 244 223 236 241 228 211 267.2
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prevalence indicator include: malignant neoplasm of floor 
of mouth (C.04.X = 1.93) and malignant neoplasm of tonsil 
(C.09.X = 1.89). Highest value of the indicator amounted to 
0.45 patient/100,000 and referred to the malignant neoplasm 
of gum (C03.X).
Discussion
This analysis groups together neoplasms of the structures 
of the oral cavity, starting from the lip and ending with the 
laryngeal and nasal parts of the throat. Individual locations 
are rare sites of neoplasm development: a few dozen to a few 
hundred cases annually, however as a group these neoplasms 
form a large category, over 4000 cases annually. Due to their 
similar aetiology and natural history, it is rational to consider 
their epidemiology as a whole. 
The basic course of information about the incidence of 
cancer is the KRN, according to which the number of new 
diagnoses in the last years has exceeded 4300 cases. The NFZ 
reports record the health services financed from public funds, 
and based on these reports approximately 4000 of new ca-
ses per year were recorded. The difference, sometimes up 
to 10%, may be caused by various methods used to create 
these sets. The differences may also result from the fact that 
the clinical differentiation of the initial point of the neoplasm 
may be problematic, in particular when the neoplasm is cli-
nically advanced in a given location. Also blurred categories, 
like C14 malignant neoplasm of other and ill-defined sites, 
C06 malignant neoplasm of other and unspecified parts of 
mouth may be used interchangeably with the codes of more 
precise categories. Cancers of H&N are much more frequently 
present in men; approximately over 70% of patients are male. 
A similar relation of men to women was demonstrated by 
studies based on the database of the International Agency 
for Research on Cancer [14]. Cancer in men more frequently 
occurs in the structures in the rear of the nose and throat 
cavity, like laryngeal or mouth part of the throat, the same 
incidence in men and women occurs only for the neoplasms 
of large salivary glands. The percentage of patients with whom 
the therapy is not continued, present on all the levels of care, 
should be assessed in a positive manner, as a manifestation 
of the care exhibited by medical professionals related to the 
suspicion of cancer, however, since this percentage is stable 
over the entire period under analysis, it seems justified to 
suggest to medical personnel, in particular to laryngologists, 
a continuous and ongoing education in the field of cancer 
diagnostics and therapy. 
Conclusions
Despite different methods of data collections and their pur-
pose, both the NFZ and the KRN data demonstrate similar 
incidence of lip, oral cavity and pharyngeal cancers. In the years 
2008–2017, a total of 46 000 cases of lip, oral cavity and pha-
ryngeal cancer were reported in hospital treatment, including 
approx. 33 000 in men and approx. 13 000 in women; annual 
average of 4200 men and 1600 women. Men constituted 
a higher percentage of patients; approx. 64% in all categories 
in total, in hospital treatment – 72%, in specialist outpatient 
care – 67%. Of all patients reported by medical institutions 
with ICD-10 diagnoses of lip, oral cavity and pharyngeal cancer 
approx. 74% end up in specialist outpatient care (specialised 
diagnostics) and approx. 27–28% end up in hospital treatment 
(enhanced diagnostics and therapy). 
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Table VII. Prevalence indicator per 100 000 inhabitants taking into account diagnoses in all types of medical services
  2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Average
C00 1.73 1.52 1.48 1.41 1.29 1.25 1.23 1.35 1.42 1.42 1.41
C01 1.17 1.10 1.06 1.02 0.85 0.85 0.88 1.03 1.11 1.10 1.02
C02 1.95 2.02 1.96 1.69 1.75 1.94 1.92 2.30 2.50 2.59 2.06
C03 0.48 0.39 0.35 0.40 0.41 0.44 0.44 0.58 0.51 0.54 0.45
C04 1.80 1.92 1.90 1.76 1.65 1.56 1.78 2.27 2.28 2.38 1.93
C05 0.74 0.74 0.75 0.61 0.54 0.61 0.58 0.74 0.76 0.74 0.68
C06 0.95 0.93 0.92 0.91 1.01 1.01 0.96 1.12 1.32 1.37 1.05
C07 0.51 0.52 0.49 0.31 0.39 0.41 0.40 0.53 0.47 0.56 0.46
C08 0.51 0.52 0.49 0.31 0.39 0.41 0.40 0.53 0.47 0.56 0.46
C09 1.98 1.72 1.56 1.46 1.53 1.65 1.68 2.32 2.55 2.44 1.89
C10 1.63 1.50 1.53 1.33 1.19 1.24 1.16 1.51 1.53 1.48 1.41
C11 1.01 1.18 0.98 0.87 0.83 0.85 0.79 0.78 1.01 0.93 0.92
C12 0.41 0.41 0.49 0.50 0.38 0.42 0.47 0.58 0.65 0.71 0.50
C13 1.94 1.65 1.64 1.58 1.56 1.65 1.60 1.88 1.98 1.93 1.74
C14 1.04 0.83 0.83 0.67 0.63 0.58 0.61 0.63 0.59 0.55 0.70
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